These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27043122)

  • 1. Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia: A 12-Month Observational Prospective Cohort Study.
    Rosso G; Pessina E; Martini A; Di Salvo G; Maina G
    J Clin Psychopharmacol; 2016 Jun; 36(3):206-12. PubMed ID: 27043122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Llorca PM; Cosar B; Petralia A; Corrivetti G; Hargarter L
    J Psychopharmacol; 2015 Aug; 29(8):910-22. PubMed ID: 25999398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia.
    Rossenu S; Cleton A; Hough D; Crauwels H; Vandebosch A; Berwaerts J; Eerdekens M; Herben V; De Meulder M; Remmerie B; Francetic I
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):270-8. PubMed ID: 27136907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia.
    Alphs L; Mao L; Lynn Starr H; Benson C
    Schizophr Res; 2016 Feb; 170(2-3):259-64. PubMed ID: 26742509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
    Alphs L; Bossie C; Mao L; Lee E; Starr HL
    Early Interv Psychiatry; 2018 Feb; 12(1):55-65. PubMed ID: 26403322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.
    Huang M; Yu L; Pan F; Lu S; Hu S; Hu J; Chen J; Jin P; Qi H; Xu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():122-130. PubMed ID: 29097257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
    J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
    Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
    Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.
    Levitan B; Markowitz M; Turkoz I; Fu DJ; Gopal S; Alphs L
    Int Clin Psychopharmacol; 2016 Nov; 31(6):315-22. PubMed ID: 27434314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia: A Real-World Multicenter, Retrospective, Mirror-Image Study.
    Devrimci-Ozguven H; Atmaca M; Baran Z; Cengisiz C; Çinar C; Erol A; Genç Y; Karadağ H; Karakülah K; Karasu U; Kaya MC; Kizil E; Özcan H; Tiryaki A; Üçok A; Varlik C; Yazar SM; Yildiz M
    J Clin Psychopharmacol; 2019; 39(6):604-610. PubMed ID: 31688391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.